The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences
Law & Policy
Swedish company issues statement after an unsourced Chinese media article claims that a probe into its licensing practices is underway
Brand name pharmaceutical companies are facing a policy-making onslaught; with their IP strategies firmly in the spotlight, many are being forced to speak up for the rights that underpin their products.
America’s life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely
From uncertainty over patent eligibility to the forces of convergence increasingly shaping the sector, IP strategy has never been more important for medical device companies.